Advertisement
FDA clears $250,000 cystic fibrosis drug

FDA clears $250,000 cystic fibrosis drug

By Steven Ross Johnson  |  July 02, 2015

Federal regulators on Thursday approved a new combination drug treatment for the most common form of cystic fibrosis. But it comes at a steep price—more than $250,000 for a year's treatment.

340B supporters cope with mounting criticism of expanded program

By Steven Ross Johnson  |  June 26, 2015

Safety net providers and clinics that participate in the 340B Drug Pricing Program will meet next month to address backlash from critics who feel the rising number of participants is a way to game the system during a period when drug prices are skyrocketing.

Hill-Rom to acquire Welch Allyn in $2 billion deal

By Adam Rubenfire  |  June 17, 2015

Hill-Rom, a Chicago-based medical equipment manufacturer, announced it will acquire Welch Allyn, a Skaneateles Falls, N.Y.-based manufacturer of diagnostic and patient-monitoring equipment.

Cardinal purchases Harvard Drug Group for $1.1B

By Adam Rubenfire  |  June 05, 2015

Cardinal Health announced Friday that it will acquire the Harvard Drug Group, a fellow pharmaceutical distributor, for about $1.1 billion. The medical-products distributor wants to strengthen its generic-drug business and expand its over-the-counter portfolio.

Koch subsidiary acquires Irish medical device firm

By Steven Ross Johnson  |  May 26, 2015

Koch Industries, run by controversial conservative billionaires Charles and David Koch, has acquired Irish medical devicemaker Protek Medical through its subsidiary Molex, the company recently announced.

Appeals court orders Actavis to continue selling Alzheimer's drug

By Lisa Schencker  |  May 22, 2015

A federal appeals court ruled Friday that Actavis must continue to sell an Alzheimer's drug it wanted to pull off the market to limit competition from generics. It's a case with potential implications for pharmaceutical companies and patients nationwide, experts say.

Johnson & Johnson expects lucrative return on drug pipeline

By Associated Press  |  May 20, 2015

Johnson & Johnson expects a lucrative return from its pharmaceutical business, with plans to seek approval by 2019 for more than 10 new products, each with the potential to top $1 billion in annual sales.

Advertisement
Modern Healthcare Daily

Award winning coverage of healthcare business and policy news.

The Modern Healthcare app includes a personalized home screen, strong search functionality and immediate downloads from the industry's leading healthcare media brand.